Tumor Biology

, Volume 34, Issue 5, pp 2891–2897 | Cite as

Overexpression of CRKL correlates with malignant cell proliferation in breast cancer

  • Tingting Zhao
  • Zhifeng Miao
  • Zhenning Wang
  • Yingying Xu
  • Jianhua Wu
  • Xingyu Liu
  • Yi You
  • Jiguang Li
Research Article


Crk-like (CRKL) is an adapter protein that has crucial roles in multiple biological processes, including cell proliferation, adhesion, and migration. However, the expression pattern of CRKL protein and its clinical significance in human breast cancers have not been well characterized. In this study, expression of CRKL was evaluated in 108 human invasive ductal carcinoma (IDC) tissues by immunohistochemistry. CRKL protein was upregulated in the cancer tissues compared with adjacent normal mammary glands. Overexpression of CRKL was found in 40 of 108 (37.03 %) breast cancer samples and correlated with advanced p-tumor–node–metastasis stage (p = 0.002), nodal metastasis (p = 0.0323), and tumor size (p = 0.0075). In addition, overexpression of CRKL in the MDA-MB-435 cell line promoted cell proliferation, and small interfering RNA knockdown of CRKL in the MDA-MB-453 cell line inhibited proliferation. Further analysis of cell cycle-related molecules showed that CRKL induced cyclin D1 and phosphorylated extracellular signal-regulated kinase expression. In conclusion, this study demonstrated that overexpression of CRKL correlated with progression and malignant proliferation of human breast cancers.


CRKL Immunohistochemistry Breast cancer Cyclin D1 


Conflicts of interest

No potential conflicts of interest were disclosed.


  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Kabbage M, Trimeche M, Ben Nasr H, Hammann P, Kuhn L, Hamrita B, et al. Expression of the molecular chaperone alphaB-crystallin in infiltrating ductal breast carcinomas and the significance thereof: an immunohistochemical and proteomics-based strategy. Tumour Biol. 2012;33(6):2279–88.CrossRefPubMedGoogle Scholar
  3. 3.
    Elfagieh M, Abdalla F, Gliwan A, Boder J, Nichols W, Buhmeida A. Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer. Tumour Biol. 2012;33(6):2371–7.CrossRefPubMedGoogle Scholar
  4. 4.
    ten Hoeve J, Morris C, Heisterkamp N, Groffen J. Isolation and chromosomal localization of CRKL, a human crk-like gene. Oncogene. 1993;8(9):2469–74.PubMedGoogle Scholar
  5. 5.
    Feller SM. Crk family adaptors-signalling complex formation and biological roles. Oncogene. 2001;20(44):6348–71.CrossRefPubMedGoogle Scholar
  6. 6.
    ten Hoeve J, Arlinghaus RB, Guo JQ, Heisterkamp N, Groffen J. Tyrosine phosphorylation of CRKL in Philadelphia + leukemia. Blood. 1994;84(6):1731–6.PubMedGoogle Scholar
  7. 7.
    ten Hoeve J, Kaartinen V, Fioretos T, Haataja L, Voncken JW, Heisterkamp N, et al. Cellular interactions of CRKL, and SH2-SH3 adaptor protein. Cancer Res. 1994;54(10):2563–7.PubMedGoogle Scholar
  8. 8.
    Senechal K, Halpern J, Sawyers CL. The CRKL adaptor protein transforms fibroblasts and functions in transformation by the BCR-ABL oncogene. J Biol Chem. 1996;271(38):23255–61.CrossRefPubMedGoogle Scholar
  9. 9.
    Hemmeryckx B, van Wijk A, Reichert A, Kaartinen V, de Jong R, Pattengale PK, et al. Crkl enhances leukemogenesis in BCR/ABL P190 transgenic mice. Cancer Res. 2001;61(4):1398–405.PubMedGoogle Scholar
  10. 10.
    Singer CF, Hudelist G, Lamm W, Mueller R, Handl C, Kubista E, et al. Active (p)CrkL is overexpressed in human malignancies: potential role as a surrogate parameter for therapeutic tyrosine kinase inhibition. Oncol Rep. 2006;15(2):353–9.PubMedGoogle Scholar
  11. 11.
    Kim YH, Kwei KA, Girard L, Salari K, Kao J, Pacyna-Gengelbach M, et al. Genomic and functional analysis identifies CRKL as an oncogene amplified in lung cancer. Oncogene. 2011;29(10):1421–30.CrossRefGoogle Scholar
  12. 12.
    Ladanyi M. CRKL as a lung cancer oncogene and mediator of acquired resistance to EGFR inhibitors: is it all that it is cracked up to be? Cancer Discov. 1(7):560-1.Google Scholar
  13. 13.
    Wang Y, Dong QZ, Fu L, Stoecker M, Wang E, Wang EH. Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer. Mol Carcinog. 2012. doi: 10.1002/mc.21935.Google Scholar
  14. 14.
    Feller SM, Knudsen B, Wong TW, Hanafusa H. Detection of SH3-binding proteins in total cell lysates with glutathione S-transferase-SH3 fusion proteins: SH3 blot assay. Methods Enzymol. 1995;255:369–78.CrossRefPubMedGoogle Scholar
  15. 15.
    Salgia R, Uemura N, Okuda K, Li JL, Pisick E, Sattler M, et al. CRKL links p210BCR/ABL with paxillin in chronic myelogenous leukemia cells. J Biol Chem. 1995;270(49):29145–50.CrossRefPubMedGoogle Scholar
  16. 16.
    Mintz PJ, Cardo-Vila M, Ozawa MG, Hajitou A, Rangel R, Guzman-Rojas L, et al. An unrecognized extracellular function for an intracellular adapter protein released from the cytoplasm into the tumor microenvironment. Proc Natl Acad Sci U S A. 2009;106(7):2182–7.PubMedCentralCrossRefPubMedGoogle Scholar
  17. 17.
    Roy PG, Thompson AM. Cyclin D1 and breast cancer. Breast. 2006;15(6):718–27.CrossRefPubMedGoogle Scholar
  18. 18.
    Sebolt-Leopold JS, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer. 2004;4(12):937–47.CrossRefPubMedGoogle Scholar
  19. 19.
    Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res. 2009;69(2):565–72.PubMedCentralCrossRefPubMedGoogle Scholar
  20. 20.
    Nosaka Y, Arai A, Miyasaka N, Miura O. CrkL mediates Ras-dependent activation of the Raf/ERK pathway through the guanine nucleotide exchange factor C3G in hematopoietic cells stimulated with erythropoietin or interleukin-3. J Biol Chem. 1999;274(42):30154–62.CrossRefPubMedGoogle Scholar
  21. 21.
    Shi Y, Chen L, Li J, Lv YL, Sun Q, Wang LX, et al. Prognostic and predictive values of pERK1/2 and pAkt-1 expression in non-small cell lung cancer patients treated with adjuvant chemotherapy. Tumour Biol. 2011;32(2):381–90.CrossRefPubMedGoogle Scholar
  22. 22.
    Dong QZ, Wang Y, Tang ZP, Fu L, Li QC, Wang ED, et al. Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. Am J Pathol. 2013;182(3):954–64.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Tingting Zhao
    • 1
  • Zhifeng Miao
    • 1
  • Zhenning Wang
    • 1
  • Yingying Xu
    • 1
  • Jianhua Wu
    • 1
  • Xingyu Liu
    • 1
  • Yi You
    • 1
  • Jiguang Li
    • 1
  1. 1.Department of Surgical Oncology and General SurgeryFirst Affiliated Hospital of China Medical UniversityShenyang CityChina

Personalised recommendations